Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours

British Journal of Cancer

Volumn 112, Issue 3, 2015, Pages 495-503

  Coutelle, O ^a   Schiffmann, L M ^a   Liwschitz, M ^a   Brunold, M ^a   Goede, V ^a,b   Hallek, M ^a   Kashkar, H ^a,c   Hacker, U T ^a,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Neurological Therapy Center   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d University Cancer Center Leipzig (UCCL)   (Germany)

Author keywords

Angiopoietin 2; basement membrane sleeves; bevacizumab; vascular normalisation; VEGF; xenograft tumours

Indexed keywords

ANGIOPOIETIN 2; BEVACIZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L1 10; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; PEPTIBODY A; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BASEMENT MEMBRANE SLEEVE; BLOOD VESSEL; CAPILLARY DENSITY; CELL HYPOXIA; CELL JUNCTION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG MEGADOSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE; VASCULARIZATION;

ANGIOPOIETIN-2; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASEMENT MEMBRANE; BLOOD VESSELS; COLONIC NEOPLASMS; DRUG SYNERGISM; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922131177     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.629     Document Type: Article

References (35)

1. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28: 2817-2823.
2. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
3. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC (2010) A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9: 145-156.
4. Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM Sorensen AG, Munn LL, Jain RK, Fukumura D (2010) Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16: 3618-3627.
5. DangDT, Chun SY, Burkitt K, AbeM, Chen S,Havre P, Mabjeesh NJ,Heath EI Vogelzang NJ, Cruz-Correa M, Blayney DW, Ensminger St WD, Croix B Dang NH, Dang LH (2008) Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res 68: 1872-1880.
6. De Bock K, Mazzone M, Carmeliet P (2011) Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8: 393-404.
7. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8: 425-437.
8. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
9. Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, Bartol A, Kienast Y Vettel C, Loos EK, Kutschera S, Bartels S, Appak S, Besemfelder E Terhardt D, Chavakis E, Wieland T, Klein C, Thomas M, Uemura A Goerdt S, Augustin HG (2012) Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 122: 1991-2005.
10. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM Kriz W, Thurston G, Augustin HG (2004) The Tie-2 ligand Angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103: 4150-4156.
11. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE (2013) Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 73: 1649-1657.
12. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG Schmiegel W, Hallek M, Hacker UT (2010) Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103: 1407-1414.
13. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV Oliner JD, McDonald DM (2010) Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70: 2213-2223.
14. Holopainen T, Saharinen P, DAmico G, Lampinen A, Eklund L, Sormunen R Anisimov A, Zarkada G, Lohela M, Helotera H, Tammela T, Benjamin LE Yla-Herttuala S, Leow CC, Koh GY, Alitalo K (2012) Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 104: 461-475.
15. Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585.
16. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109: 17561-17566.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
18. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels and appearance of basement membrane ghosts. Am J Pathol 165: 35-52.
19. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
20. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
21. Kabbinavar F (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
22. Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K Augustin HG, Thomas M (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent anti-tumor, anti-angiogenic, and antimetastatic efficacy. Clin Cancer Res 19: 6730-6740.
23. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, Kim M, Kim KE, Kim H Lim NK, Jeon CJ, Lee GM, Jeon BH, Nam DH, Sung HK, Nagy A, Yoo OJ Koh GY (2010) Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18: 171-184.
24. Lalande ME, Ling V, Miller RG (1981) Hoechst 33342 dye uptake as a probe of membrane permeability changes in mammalian cells. Proc Natl Acad Sci USA 78: 363-367.
25. Mancuso MR, Davis R, Norberg SM, OBrien S, Sennino B, Nakahara T, Yao VJ Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621.
26. MazzoneM, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian Y-M Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S Aragones J, Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136: 839-851.
27. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C Schadendorf D, Thurston G, Fiedler U, Augustin HG (2009) Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333.
28. Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ Wolf GL, Fischman A, Boucher Y, Jain RK (1999) Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 96: 3137-3142.
29. Ooyama A, Oka T, Zhao H, Yamamoto M, Akiyama S, Fukushima M (2008) Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenograftsCancer Lett 267: 26-36.
30. Rolny C, MazzoneM, Tugues S, Laoui D, Johansson I, Coulon C, SquadritoML Segura I, Li X, Knevels E (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
31. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
32. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11): 3731-3736.
33. Van der Veldt AaM, Lubberink M, Bahce I, Walraven M, de Boer MP Greuter HNJM, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE Verheul HM, Serne EH, Lammertsma AA, Smit EF (2012) Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21: 82-91.
34. Zhou Q, Gallo JM (2009) Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol 11: 301-310.
35. Zhou Q, Guo P, Gallo JM (2008) Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 14: 1540-1549.